<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Introduction of drug-eluting stents (DES) in the therapy of patients with coronary artery disease resulted in the significant reduction of in-stent restenosis compared to bare-metal stent (BMS) treatment. However, the high incidence of late stent thrombosis with DES emerged as one of the safety concerns after their implantation. Enhancing stent endothelization by improved early healing and neointimal strut coverage emerged as possible solution for this late complication. Endothelial progenitor cells (EPC) capturing stents are designed to promote in situ endothelization with immobilized, antihuman, anti-CD34 antibodies attached to the luminal stent surface. Anti-CD34 antibodies target and capture EPC from circulation, which further differentiate into vascular endothelial cells and form functional endothelial layer on the stent surface. These cells are also capable of secreting pro-angiogenic factors that stimulate local endothelial cells to proliferate and migrate. Preclinical and clinical studies proved feasibility, efficacy and safety of EPC capturing stents in stable and high-risk patients with coronary artery disease. Rapid and extensive endothelization of EPC capturing stents translated into favorable profile of clinical outcomes, comparable to efficacy of BMSs and DESs. Therefore, we here present the most important results from the experimental and clinical studies that explored ECP capturing strategy to enhance endothelization, reduce the incidence of instent thrombosis and improve outcomes of patients with coronary artery disease, along with the future perspectives in this promising therapeutic approach.</p></abstract>

Introduction of drug-eluting stents (DES) in the therapy of patients with coronary artery disease resulted in the significant reduction of in-stent restenosis compared to bare-metal stent (BMS) treatment. However, the high incidence of late stent thrombosis with DES emerged as one of the safety concerns after their implantation. Enhancing stent endothelization by improved early healing and neointimal strut coverage emerged as possible solution for this late complication. Endothelial progenitor cells (EPC) capturing stents are designed to promote in situ endothelization with immobilized, antihuman, anti-CD34 antibodies attached to the luminal stent surface. Anti-CD34 antibodies target and capture EPC from circulation, which further differentiate into vascular endothelial cells and form functional endothelial layer on the stent surface. These cells are also capable of secreting pro-angiogenic factors that stimulate local endothelial cells to proliferate and migrate. Preclinical and clinical studies proved feasibility, efficacy and safety of EPC capturing stents in stable and high-risk patients with coronary artery disease. Rapid and extensive endothelization of EPC capturing stents translated into favorable profile of clinical outcomes, comparable to efficacy of BMSs and DESs. Therefore, we here present the most important results from the experimental and clinical studies that explored ECP capturing strategy to enhance endothelization, reduce the incidence of instent thrombosis and improve outcomes of patients with coronary artery disease, along with the future perspectives in this promising therapeutic approach.

Capturing Endothelial Cells by Coronary Stents - From Histology to Clinical Outcomes

Clinic of Cardiology, Clinical Center of Serbia

Faculty of Medical Sciences, Department of Internal Medicine,

Institute of Histology and Embryology “Aleksandar Dj. Kostic”, School of Medicine

Experimental and Applied Biomedical Research (EABR)

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Introduction of drug-eluting stents (DES) in the therapy of patients with coronary artery disease resulted in the significant reduction of in-stent restenosis...

Capturing Endothelial Cells by Coronary Stents - From Histology to Clinical Outcomes

Publié en ligne: 15 nov. 2019

Pages: -

Reçu: 03 oct. 2018

Accepté: 03 oct. 2018

DOI: https://doi.org/10.2478/sjecr-2019-0018

Mots clés
coronary stent, endothelial progenitor cells, drug-eluting stent, bare metal stent, coronary artery disease

© 2019 Miloje Tomasevic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Capturing Endothelial Cells by Coronary Stents - From Histology to Clinical Outcomes

Publié en ligne: 15 nov. 2019

Pages: -

Reçu: 03 oct. 2018

Accepté: 03 oct. 2018

DOI: https://doi.org/10.2478/sjecr-2019-0018

Mots cléscoronary stent, endothelial progenitor cells, drug-eluting stent, bare metal stent, coronary artery disease

© 2019 Miloje Tomasevic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
coronary stent, endothelial progenitor cells, drug-eluting stent, bare metal stent, coronary artery disease